COAG
Income statement / Annual
Last year (2025), Hemab Therapeutics Holdings Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Hemab Therapeutics Holdings Inc.'s net income was -$63.91 M.
See Hemab Therapeutics Holdings Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
| Period Ended |
12/31/2025 |
| Operating Revenue |
$0.00 |
| Cost of Revenue |
$0.00
|
| Gross Profit |
$0.00
|
| Gross Profit Ratio |
0
|
| Research and Development Expenses |
$59.63 M
|
| General & Administrative Expenses |
$10.49 M
|
| Selling & Marketing Expenses |
$0.00
|
| Selling, General & Administrative Expenses |
$10.49 M
|
| Other Expenses |
$0.00
|
| Operating Expenses |
$70.12 M
|
| Cost And Expenses |
$70.12 M
|
| Interest Income |
$1.97 M
|
| Interest Expense |
$0.00
|
| Depreciation & Amortization |
$304.00 K
|
| EBITDA |
-$69.82 M |
| EBITDA Ratio |
0
|
| Operating Income Ratio |
0
|
| Total Other Income/Expenses Net |
$5.98 M
|
| Income Before Tax |
-$64.14 M
|
| Income Before Tax Ratio |
0
|
| Income Tax Expense |
-$227.00 K
|
| Net Income |
-$63.91 M
|
| Net Income Ratio |
0
|
| EPS |
-2.33 |
| EPS Diluted |
-2.33 |
| Weighted Average Shares Out |
$27.44 M
|
| Weighted Average Shares Out Diluted |
$27.44 M
|
| Link |
|
